MediLink Therapeutics Enters into a Collaboration and License Agreement with Roche to Develop and Commercialize YL211 for Solid Tumors
Shots:
- MediLink will grant Roche exclusive global rights for the development, manufacturing & commercialization of YL211. Both companies will jointly initiate the P-I clinical evaluation of YL211 at Roche’s R&D unit CICoR following which Roche will be responsible for further development & commercialization globally
- As per the agreement, Medilink will receive an aggregate of $50M in up front & near-term milestone payments & additional development, regulatory & commercial milestone payments potentially adding to a total deal value of ~$1B plus tiered royalties
- YL211 is an ADC that specifically targets c-Mesenchymal-epithelial transition factor (c-Met) associated with tumor formation, aggressive growth & metastasis
Ref: PR Newswire | Image: Roche
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
